• Corpus ID: 77410517

Quide vs. Mellaril in chronic schizophrenic patients.

  title={Quide vs. Mellaril in chronic schizophrenic patients.},
  author={Gallant Dm and Bishop Mp},
  journal={Current Therapeutic Research-clinical and Experimental},
  • Gallant Dm, Bishop Mp
  • Published 1972
  • Medicine
  • Current Therapeutic Research-clinical and Experimental
8 Citations
Thioridazine for schizophrenia.
Although there are shortcomings, there appears to be enough consistency over different outcomes and periods to confirm that thioridazine is an antipsychotic of similar efficacy to other commonly used antipsychotics for people with schizophrenia.
The relative importance of genetic and environmental factors in hypertension in black subjects.
  • A. Aderounmu
  • Medicine
    Clinical and experimental hypertension
  • 1981
Differences occur in the prevalence and severity of the disease among the black racial groups, and genetic factors may be the only important considerations in the severity of hypertension in black subjects.
Plasma concentrations of thioridazine metabolites and ECG abnormalities.
In four of the five patients, abnormal ECG's were found whenever plasma concentrations of the thioridazine ring sulfoxide were elevated, and no relationship could be detected between the appearance of ECG abnormalities and the concentrations of thIORidazine and its other metabolites.
Piperacetazine Versus Thioridazine in the Treatment of Organic Brain Disease: A Controlled Double‐Blind Study
Piperacetazine proved to be at least as effective as thioridazine and seemed to be more effective against certain target symptoms; side effects were less common and less severe.
Letter: Fatal aplastic anemia with piperacetazine therapy.
Piperacetazine, a piperidine derivative of phenothiazine introduced in 1961 for treatment of schizophrenia, has been shown to be an effective tranquilizer, safe for short-term use and good for long-term protection against infectious disease.
Penfluridol: an efficacious long-acting oral antipsychotic compound.
It is indicated that weekly administration of penfluridol (one oral dose) provides relatively safe and adequate control of severely ill schizophrenic patients and displays efficacy similar to that of the shorter-acting antipsychotic agents.